Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

L. Voncina; B. B. Godman; V. Vlahovic-Palcevski; M. Bennie; I. Bishop

doi:10.1002/pds.2206

Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

L. Voncina, B. B. Godman, V. Vlahovic-Palcevski, M. Bennie, I. Bishop

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Conference Contribution › peer-review

6 Citations (Scopus)

Abstract

Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

Original language	English
Article number	482
Pages (from-to)	S210-S210
Journal	Pharmacoepidemiology and Drug Safety
Volume	20
Issue number	Suppl.1
DOIs	https://doi.org/10.1002/pds.2206
Publication status	Published - 2011
Event	27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management - Chicago, United States Duration: 14 Aug 2011 → 17 Aug 2011

Keywords

receptor blockers
drug utilisation
Croatia

Access to Document

10.1002/pds.2206

Cite this

@article{9a87e9e22b0d45d39a96b862fc17a732,

title = "Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future",

abstract = "Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.",

keywords = "receptor blockers, drug utilisation, Croatia",

author = "L. Voncina and Godman, {B. B.} and V. Vlahovic-Palcevski and M. Bennie and I. Bishop",

year = "2011",

doi = "10.1002/pds.2206",

language = "English",

volume = "20",

pages = "S210--S210",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

number = "Suppl.1",

note = "27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management ; Conference date: 14-08-2011 Through 17-08-2011",

}

TY - JOUR

T1 - Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

AU - Voncina, L.

AU - Godman, B. B.

AU - Vlahovic-Palcevski, V.

AU - Bennie, M.

AU - Bishop, I.

PY - 2011

Y1 - 2011

N2 - Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

AB - Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

KW - receptor blockers

KW - drug utilisation

KW - Croatia

U2 - 10.1002/pds.2206

DO - 10.1002/pds.2206

M3 - Conference Contribution

SN - 1053-8569

VL - 20

SP - S210-S210

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

IS - Suppl.1

M1 - 482

T2 - 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Y2 - 14 August 2011 through 17 August 2011

ER -

Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

Abstract

Keywords

Access to Document

Fingerprint

Cite this